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Abstract: Background: Diabetic neuropathy is defined as the dysfunction of the peripheral nervous
system in diabetic patients. It is considered a microvascular complication of diabetes mellitus. Its
presence is associated with increased morbidity and mortality. Although several studies have found
alterations at somatic motor, sensory levels and at the level of autonomic nervous system in diabetic
patients, there is not a systematic approach regarding the differences in neuropathy between the major
variants of diabetes, e.g., type 1 and 2 diabetes at both neurological and molecular level. Data sources:
we systematically (Medline, Scopus, and Cochrane databases) evaluated the literature related to
the difference of neuropathy in type 1 and 2 diabetes, differences in molecular biomarkers. Study
characteristics: seventeen articles were selected based on pre-defined eligibility criteria. Conclusions:
both superficial sensitivity (primarily thermal sensitivity to cold) and deep sensitivity (such as
vibratory sensitivity), have been reported mainly in type 2 diabetes. Cardiac autonomic neuropathy
is one of the diabetic complications with the greatest impact at a clinical level but is nevertheless
one of the most underdiagnosed. While for type 1 diabetes patients most neuropathy alterations
have been reported for the Valsalva maneuver and for the lying-to-standing test, for type 2 diabetes
patients, alterations have been reported for deep-breathing test and the Valsalva test. In addition,
there is a greater sympathetic than parasympathetic impairment, as indicated by the screening
tests for autonomic cardiac neuropathy. Regarding subclinical inflammation markers, patients
with type 2 diabetes showed higher blood levels of inflammatory markers such as high-sensitivity
C-reactive protein, proinflammatory cytokines IL-6, IL-18, soluble cell adhesion molecules and E-
selectin and ICAM-1, than in type 1 diabetes patients. By contrast, the blood levels of adiponectin,
an adipocyte-derived protein with multiple paracrine and endocrine activities (anti-inflammatory,
insulin-sensitizing and proangiogenic effects) are higher in type 1 than in type 2 diabetic patients.
This review provides new insights into the clinical differences in type 1 and 2 diabetes and provide
future directions in this research field.
Keywords: cytokines; vibratory sensitivity; thermal sensitivity; muscle; biomarkers; insulin
1. Introduction
Diabetes is a chronic, metabolic disease characterized by elevated levels of blood
glucose, which leads over time to serious damage to the heart, blood vessels, eyes, kidneys,
and nerves. Its consequences are one of the most serious public health problems with a
considerable impact on both human and health resources. Diabetes not only affects the
individual’s functionality and quality of life, it is also associated with premature mortality
as well as increased morbidity [1]. There are several forms of diabetes [2–4]. Type 1
diabetes is a chronic autoimmune disease characterized by the pancreas losing the ability
to generate insulin, the hormone that regulates hyperglycemia. For this reason, people
with type 1 diabetes will require daily insulin administration for life. Type 2 diabetes is
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characterized by the presence of high blood glucose levels due to the body’s resistance
to insulin, which means that although this hormone is present in the circulation, the cells
cannot use it properly to introduce the sugar into their interior. The main causes of insulin
resistance are lack of physical activity and the accumulation of adipose tissue, so excess
weight and a sedentary lifestyle seem to be the main risk factors for the development of this
disease. Maturity Onset Diabetes in the Young (MODY) is caused by genetic defects of the
pancreatic beta cells due to different genetic alterations, presented as autosomal dominant
inherited disorders leading to a defect in insulin secretion. Cystic fibrosis related diabetes
is a genetic disease that affects multiple organs including the pancreas, which can lead to
the development of diabetes. Diabetes can be secondary to the effects of some medications
(for examples glucocorticoids and immunosuppressants drugs) that can alter the secretion
or action of insulin. Pregnancy puts a great metabolic strain on the mother’s body, which
can sometimes lead to some insulin resistance. As a result, the pancreas has to produce
more insulin to get glucose into the cells and reduce its accumulation in the blood, and
sometimes this organ is unable to secrete enough of the hormone, so blood glucose levels
rise leading to gestational diabetes and glucose intolerance resembling type 2 diabetes. The
most prevalent types of diabetes are type 1 and 2, but type 2 diabetes is up to 10 times
more frequent than type 1 diabetes. The incidence of type 1 diabetes increases with age
until it reaches its peak at around 10 to 14 years of age, but the disease can debut at any
age [5]. Meanwhile, the peak of the incidence of type 2 diabetes is later, at between 55 and
59 years old [6]. Type 1 and 2 diabetes show a slightly higher prevalence in men than in
women. An estimated 462 million people worldwide, the equivalent to 6.28% of the world’s
population, are affected by type 2 diabetes. The global incidence of type 1 diabetes began
to rise in the 1950s with an average annual increase of 3–4% over the past three decades,
and incidences of approximately 10–20 cases per 100,000 population in southern Europe
and the United States of America [1,6]. Healthcare expenditure on diabetes care is at least
3.2 times higher than the calculated average per capita and increases to 9.4 times in the
presence of complications. In terms of functionality, diabetes is among the top 10 disabling
diseases [5], and among its diabetic complications, neuropathy affects quality of life and
is associated with an increased risk of amputations [7,8], morbidity and mortality [9,10].
Diabetic peripheral neuropathy is the most common form of neuropathy worldwide. The
most recent studies in Europe and the United States of America indicate a prevalence of
diabetic peripheral neuropathy ranging from 6 to 51% of the population of people with
diabetes. The prevalence of diabetic peripheral neuropathy in adults with type 1 diabetes
is 6% at the onset of the disease, increasing to 30% after 13–14 years of progression [11,12].
This prevalence is somewhat higher among people with type 2 diabetes and is present in
26% of young people with type 2 diabetes. Among adults with diabetes, about 40% of
patients at cardiovascular risk have peripheral neuropathy [11].
Risk factors for the development of neuropathy include different variables such as age,
duration of diabetes, glycemic control, and comorbidities such as hypercholesterolemia,
hypertension, obesity, and smoking. With regard to diabetic neuropathy, studies reporting
the prevalence of peripheral neuropathy in young people with diabetes have determined
rates of 7% in patients with type 1 diabetes and 22% with type 2 diabetes [13].
These data suggest a difference in the pathophysiological mechanisms of diabetic
neuropathy between patients with type 1 and type 2 diabetes. Given the characterization of
the eventual differences between neuropathy in people with type 1 and type 2 diabetes, it is
important to know the best tool to assess them, in order to treat and prevent their adverse
effects, and to be able to plan specific care depending on the manifestations of neuropathy
that may occur in the two most frequent types of diabetes. This review aims to clarify these
aspects, which we believe to be fundamental in an individualized approach to diabetes
neuropathy, biomarkers investigations and appropriated interventions at a clinical and
community level, depending on the type of patient with diabetes being treated.
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2. Materials and Methods
This study was designed and developed according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) [14] guidelines, which represent
an evidence-based minimum set of items aimed at assessing the benefits and harms of a
healthcare intervention.
2.1. Literature Search
We searched the literature in multiple electronic bibliographic databases (Medline,
Scopus, and Cochrane), covering all entries until 31 July 2020. The reference lists of all the
relevant articles were manually cross-referenced in order to identify additional articles. The
primary search terms used were “neuropathy” and “diabetes”, with one of the following
terms: “type I and II (or 1 and 2)”, “difference”, “gender/sex differences”, “sensory”,
“motor”, “autonomic”. We used the Medical Subject Headings (MeSH) thesaurus to find
standard descriptors and their synonyms related to the area of knowledge to be studied.
We used these terms to construct the search equation, which was made up of three main
components that were semantically related to many other descriptors that were included
in the equation. These three parts of the equation were: autonomy * neuropathy, somatic
neuropathy, and diabetes mellitus, and they were joined by the Boolean operator “AND”,
with their related terms connected by the operator “OR”.
2.2. Inclusion and Exclusion Criteria
We applied the following inclusion criteria in order to answer the research question:
(1) acknowledged as an original article including reports with different experimental
designs such as experimental studies (randomized and placebo-controlled trials) and
observational studies (cohort and cross-sectional studies, case series, and case–control
studies); (2) full text published in either English or Spanish; (3) neuropathy was specifically
assessed in the Methods section by physiological assessments and/or specific neuropathy
questionnaires; (4) the authors separately analyzed the outcomes in type 1 and type 2
diabetic patients.
2.3. Data Collection and Analysis
The database search results were uploaded into a web-based system which was used to
manage the screening process, and duplicate citations were removed. To determine which
studies would be included, three members of the review team independently screened the
title and abstracts of the articles extracted from the literature search. The electronic full text
was retrieved for studies on which the reviewers agreed, based on our inclusion/exclusion
criteria. Two reviewers independently extracted the following data for each of these
articles: the country where the study was conducted, the number of participants, the
age of participants at the time of inclusion, their sex, the assessment tools for evaluating
neuropathy, the differences between type 1 and 2 diabetic patients, and the main outcomes:
sensory, motor, and autonomic neuropathy, biomarkers and effects of age and gender. Any
disagreement between the two reviewers regarding the papers and data extracted from
them was resolved by the third author.
3. Results
A total of 259 papers were retrieved from the studies identified by our search strategy;
after eliminating duplicates, 26 met the inclusion criteria and were analyzed in detail;
finally, 17 articles fulfilled the criteria and aims of this review (Figure 1). Most articles
were excluded because they did not compare the presence and/or severity of neuropathy
between type 1 and 2 diabetes. Two researchers independently summarized the results
which emerged from this literature review under five headings: (1) Differences in sensory
neuropathy; (2) Differences in motor neuropathy; (3) Differences in autonomic neuropathy;
(4) Differences in markers associated with neuropathy in type 1 and 2 diabetes; (5) Effect of
age and sex on neuropathy in type 1 and 2 diabetes.
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Figure 1. Systematic review workflow.
The most important variables of the selected studies are summarized in Tables 1–3,
and their results are shown and discussed in the respective sections.
3.1. Sensory Neuropathy
The main characteristics of the studies comparing type 1 and 2 diabetic patients regard-
ing impairment of sensitivity are shown in Table 1. Regarding the thermal-analgesic sensi-
tivity which shares common anatomical routes (superficial sensitivity) three studies found
thermal sensitivity is more impaired in type 2 patients than in type 1 patients [17,19,21].
Cold sensitivity impairment was higher in type 2 patients than in type 1 patients (60%
versus 40%, respectively), whereas impairment in warm sensitivity was only found in
10% of type 1 patients and in no type 2 diabetic patients [17]. No significant differences
were found between type 1 and 2 patients for cold and heat sensitivity [33]. Impairment
of pain sensitivity was not reported in any group of type 1 and 2 diabetic patients in one
study [17]. For deep sensitivity, impairment in palestesic (vibratory) sensitivity recorded
in the malleolus and hallux was higher in type 2 than in type 1 diabetic patients, and was
demonstrated across a varied age range (mean age 15–62 years old) [15,17,19,33]. The
presence of the palestesic sensitivity, defined as being more than 2 standard deviations
below the mean value in normal controls, was found in 40% of type 2 diabetics and in
12% approximatively of type 1 diabetic patients [17], and not found in type 1 diabetics [33]
thus reinforcing the data on higher threshold values in type 2 than in type 1 patients.
This higher threshold for vibration sensitivity is accompanied by a lower amplitude and
conduction velocity of the sural sensory nerve, present in both types of diabetes without
any differences [15]. In other studies, the nerve conduction rate in some sensory nerves,
e.g., the median nerve (but not in other nerves such as the ulnar and sural nerves) was
lower in type 2 than in type 1 diabetes patients [21].
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Table 1. Differences between type 1 (T1) and type 2 (T2) diabetes in sensory neuropathy.








The vibration perception threshold in the malleolus and hallux,
was higher in type 1 diabetics than in type 2 diabetics.
No differences were found in amplitude, conduction velocity and
distal latency of sural sensory nerve, between type 1 and type
2 diabetics.
Mean duration of DM
T1 22.1 ± 11.1
T2 14.0 ± 9.0
Level of glycemic control (HbA1c) (%) T1 7.44 ± 1.38
T2 7.08 ± 1.45
Gender (%)
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Pain a d hermal s nsitivity tester [18]
Diapason
The frequency of cold sensitivity impairment was higher in type
2 diabetic than in type 1 (60% vs. 40%)
The impairment of heat sensitivity was only found in 10% of type
1 diabetics.
The frequency of vibration sensitivity impairment was higher in
type 2 diabetics than in type 1 (45% vs. 15%)
The impairment of pain sensitivity was not found in neither group
of diabetics.
Mean duration of DM
T1 7.8 ± 2.3
T2 10.4 ± 2.4
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T2 8.3 ± 0.3
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great toe.
The pr valence of sensory neuropathy was higher in type 2
diabetics than in type 1 diabetics.
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T2 6.6
Gender (%)
J. Pers. Med. 2021, 11, x FOR PEER REVIEW 4 of 18 
 
 
which emerged from this literature review under five headings: (1) Differences in sensory 
neuropathy; (2) Differences in motor neuropathy; (3) Differences in autonomic neuropa-
thy; (4) Differences in markers associated with neuropathy in type 1 and 2 diabetes; (5) 
Effect of age and sex on neuropathy in type 1 and 2 diabetes. 
 
Figure 1. Systematic revi w workflow. 
The most important variables of the selected studies are summarized in Tables 1–3, 
and their results are shown and discussed in the respective sect s. 
Table 1. Differences between type 1 (T1) and type 2 (T2) diabetes in sensory neuropathy. 
Reference Population Characteristics Measurement of Neuropathy M in Outcomes 
Balducci et 
al. 2014 [15] 
N 400 
Questionnaire Michigan Neuropathy 
Screening Instrument [16] 
 
Diapason and biothesiometer 
 
Monofilament 
The vibration perception threshold in the malleolus 
and hallux, was higher in type 1 diabetics tha  in type 
2 diabetics. 
No differenc s were found in amplitude, cond ctio  
velocity and distal latency of sural ensory nerve, 
betwe n type 1 and type 2 diabetics. 
Mea ur tion 
of DM 
T1 22.  ± 1.1 





7.44 1 8 




Age (mean) 61.9 ± 11.1 
Meyer et al. 
2003 [17] 
N 42 
Pain and thermal sensitivity tester [18] 
 
Diapason 
The frequency of cold sensitivity impairment was 
higher in type 2 diabetics than in type 1 (60% vs. 40%) 
The impairment of heat sensitivity was only found in 
10% of type 1 diabetics. 
The frequency of vibration sensitivity impairment was 
higher in type 2 diabetics than in type 1 (45% vs. 15%) 
The impairment of pain sensitivity was not found in 
neither group of diabetics. 
Mean dur tion 
of DM 
T1 7.8 ± 2.3 





T1 9.4 ± 0.6 
T2 8.3 ± 0.3 
Gender (%) ♀ 54.8% 
♂ 45.2% 
Age (mean) 46.3 ± 2 
49%
J. Pers. Med. 2021, 11, x FOR PEER REVIEW 4 of 18 
 
 
which emerged from this literature review under five headings: (1) Differences in sensory 
neuropathy; (2) Differences in motor neuropathy; (3) Differences in autonomic neuropa-
thy; (4) Differences in markers associated with neuropathy in type 1 and 2 diabetes; (5) 
Effect of age and sex on neuropathy in type 1 and 2 diabetes. 
 
Figure 1. Systematic review workflow. 
The most important variables of the selected studies are summarized in Tables 1–3, 
and their results are shown and discussed in the respective sections. 
Table 1. Differences between type 1 (T1) and type 2 (T2) diabetes in sensory neuropathy. 
Reference Population Characteristics Measurement of N uropathy M in Outcomes
Balducci et 
al. 2014 [15] 
N 400 
Questionnaire Michigan Neuropathy 
Screening Instrument [16] 
 
Diapason and biothesiome  
Monofilament 
The vibration perception threshold in the malleolus 
and hallux, was higher in type 1 diabetics than in type 
2 diabetics. 
No differenc s were found in amplitude, conduction 
velocity and distal latency of sural sensory nerve, 
between type 1 and type 2 diabetics. 
Mea  uration 
of DM 
T1 22.1 ± 11.1 





 7.44 ± 1.38 
T2 7.08 ± 1.45 
Gender (%) ♀ 
43% 
♂ 57% 
Age (mean 61.9 ± 11.1 
Meyer et al. 
2003 [17] 
N 42 
Pain and thermal sensitivity tester [18] 
 
Diapason 
The frequency of cold sensitivity impairment was 
higher in type 2 diabetics than in type 1 (60% vs. 40%) 
The impairment of heat sensitivity was only found in 
10% of type 1 diabetics. 
The frequency of vibration sensitivity impairment was 
higher in type 2 diabetics than in type 1 (45% vs. 15%) 
The impairment of pain sensitivity was not found in 
neither group of diabetics. 
Mean duration 
of DM 
T1 7.8 ± 2.3 





T1 9.4 ± 0.6 
T2 8.3 ± 0.3 
Gender (%) ♀ 54.8% 
♂ 45.2% 
Age (mean) 46.3 ± 2 
51%




Questionnaire Neuropathy Disability Score and
Questionnaire Neuropathy Symptom Score [22]
Electromyography
The prevalence of sensory neuropathy was higher in type 2
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conduction rate.
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Score (NSS) were also more altered in type 2 diabetics.
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Questionnaire Michigan Neuropat y Screening
Instrument [16]
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limbs.
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and distal latency of motor peroneal nerve and sensory
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Mean duration of DM
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Questionnaire Neuropathy Disability Score and
Questionnaire Neuropathy Symptom Score [22]
Electromyography:
→Conduction velocity of medium, ulnar, and peroneal
motor nerves.
The prevalence of motor neuropathy was higher in type 2 diabetics.
Neuropathy Disability Score (NDS) and Neuropathy Symptom
Score (NSS) were also more altered in type 2 diabetics.
Mean duration of DM
T1 161
2 Notreported
Level of glycemic control (HbA1c) (%) T1 6.91 ± 1.70
2 6.53 ± 1.09
Gender (%)
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Total Neuropathy Score [25]
Electromyography:
→Conduction velocity of motor nerves
Nerve excitability testing:
→Compound muscle action potentials of median motor
nerve at the wrist
Abnormalities in nerve excitability parameters were found in type
1 diabetes patients.
Mean duration of DM
T1 7.78 ± 1.33
T2 8.07 ± 1.14
Level of glycemic control (HbA1c) (%) T1 7.64 ± 0.33
T2 7.70 ± 0.39
Gender (%)
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Table 3. Differences between type 1 (T1) and type 2 (T2) diabetes in autonomic neuropathy.




CV autonomic reflex tests: heart rate variation
during rest, to deep breathing, to cough test,
to standing, systolic blood pressure falls on
standing.
No differences we e found for the systolic blood press re response to standing, between type 1
diabetics and type 2 diabetics.
Heart rate response to deep breathing was higher in type 1 diabetics than in type 2.
Heart rate response to standing was higher in type 1 diabetics than in type 2.




T1 22.1 ± 11.1
T2 14.0 ± 9.0
Level of glycemic
control (HbA1c) (%)
T1 7.44 ± 1.38
T2 7.08 ± 1.45
Gender (%)
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CV autonomic reflex tests: heart rate variation
during rest, to deep breathing, to
Valsalva maneuver.
Peripheral sympathetic test: laser doppler
anemometry for vasomotion assessment.
In type 1 diabetes patients, vasomotion impairment was more common in subjects with autonomous
neuropathy than in those without it. In contrast, in type 2 diabetics group, no differences were found
n deterioration of vasomotion betwee subjects with and subjects without autonomic neuropathy.
Type 1 diabetics who did not suffer autonomic neuropathy had vasomotion amplitudes greater than
those with autonomic neuropathy while in type 2 diabetics, no differences were observed.
In both type 1 and type 2 diabetics, a positive association was found between vasomotion
amplitudes and Valsalva ratio.
Th re no was correlat on between vasomotion amplitudes and variation heart rate during deep
breathing test, in neither group.
Mean duration
of DM
T1 7.8 ± 2.3
T2 10.4 ± 2.4
Level of glyce ic
control (HbA1c) (%)
T1 9.4 ± 0.6
8.3 ± 0.3
Gender (%)
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Table 3. Cont.
Reference Population Study Characteristics Measurement of Neuropathy Main Outcomes
Gulichsen
et al. 2012 [29]
N 323
CV autonomic reflex tests using a new
handheld device VagusTM [30]: heart rate
variation during rest, heart rate response to
deep breathing, to Valsalva maneuver, to
standing.
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retinopathy and patients without retinopathy, in neither diabetic group.
Rec very of sy tolic and diastolic BP at 2 minutes post exercise was not different between those
diabetics with retinopathy and those without, in the group of type 1 diabetics. In contrast, in type 2
diabetics, the recovery of SBP was higher in subjects with retinopathy, while this difference was not
observed for DBP.
In both groups of diabetics, univariate analysis showed a significant and positive correlation
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Determination of QTc interval (ECG)
In both diabetic groups, QTc dispersion was longer than in healthy controls, but this difference only
was significant in type 2 diabetics.
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Table 3. Cont.
Reference Population Study Characteristics Measurement of Neuropathy Main Outcomes
Palasciano
et al. 1992 [34]
N 21
Electromyography:
Function of the striatum muscle.
Conduction velocity and potential amplitude
of deep peroneal motor nerves. Ultrasound
for evaluate gallbladder volume and study
motor function (motility), during fasting and
after intake.










J. Pers. Med. 2021, 11, x FOR PEER REVIEW 4 of 18 
 
 
which emerged from this literature review under five headings: (1) Differences in sensory 
neuropathy; (2) Differences in motor neuropathy; (3) Differences in autonomic neuropa-
thy; (4) Differences in markers associated with neuropathy in type 1 and 2 diabetes; (5) 
Effect of age and sex on neuropathy in type 1 and 2 diabetes. 
 
Figure 1. Systematic review workflow. 
The most important variables of the selected studies are summarized in Tables 1–3, 
and their results are shown and discussed in the respective sections. 
Table 1. Differences between type 1 (T1) and type 2 (T2) diabetes in sensory neuropathy. 
Reference Population Characteristics Measurement of Neuropathy Main Outcomes 
Balducci et 
al. 2014 [15] 
N 400 
Questionnaire Michigan Neuropathy 
Screening Instrument [16] 
 
Diapason and biothesiometer 
 
Monofilament 
The vibration perception threshold in the malleolus 
and hallux, was higher in type 1 diabetics than in type 
2 diabetics. 
No differences were found in amplitude, conduction 
velocity and distal latency of sural se s ry nerve, 
between type 1 and type 2 diabetics. 
Mean duration 
of DM 
T1 22.1 ± 11.1 
T2 14.0 ± 9.0 
Level of 
glycemic 
c ntrol (HbA1c) 
(%  
T1 7.44 ± 1.38 
2 7.08 ± 1.45 
Gender (%) ♀ 
43% 
♂ 57% 
Age (mean) 61.9 ± 11.1 
Meyer et al. 
2003 [17] 
N 42 
Pain and thermal sensitivity tester [18] 
 
Diapason 
The frequency of cold sensitivity impairment was 
higher in type 2 diabetics than in type 1 (60% vs. 40%) 
The impairment of heat sensitivity was only found in 
10% of type 1 diabetics. 
The frequency of vibration sensitivity impairment was 
higher in type 2 diabetics than in type 1 (45% vs. 15%) 
The impairment of pain sensitivity was not found in 
neither group of diabetics. 
Mean duration 
of DM 
T1 7.8 ± 2.3 





T1 9.4 ± 0.6 
T2 8.3 ± 0.3 
Gender (%) ♀ 54.8% 
♂ 45.2% 
Age (mean) 46.3 ± 2 
52%
J. Pers. Med. 2021, 11, x FOR PEER REVIEW 4 of 18 
 
 
which emerged from this literature review under five headings: (1) Differences in sensory 
neuropathy; (2) Differences in motor neuropathy; (3) Differences in autonomic neuropa-
thy; (4) Differences in markers associated with neuropathy in type 1 and 2 diabetes; (5) 
Effect of age and sex on neuropathy in type 1 and 2 diabetes. 
 
Figure 1. Systematic review workflow. 
The most important variables of the selected studies are summarized in Tables 1–3, 
and their results are shown and discussed in the respective sections. 
Table 1. Differences between type 1 (T1) and type 2 (T2) diabetes in sensory neuropathy. 
Reference Population Characteristics Measurement of Neuropathy Main Outcomes 
Balducci et 
al. 2014 [15] 
N 400 
Questionnaire Michigan Neuropathy 
Screening Instrument [16] 
 
Diapason and bio hesiometer 
 
Monofilament 
The vibration perception threshold in the malleolus 
and hallux, was higher in type 1 diabetics than in type 
2 diabetics. 
No differences were found in amplitude, conduction 
velocity and distal latency of sural sensory nerve, 
between type 1 and type 2 diabetics. 
Mean duration 
of DM 
T1 22.1 ± 11.1 





 7.44 ± 1.38 
T2 7.08 ± 1.45 
Gender (%) ♀ 
43% 
♂ 57% 
Age (mean) 61.9 ± 11.1 
Meyer et al. 
2003 [17] 
N 42 
Pain and thermal sensitivity tester [18] 
 
Diapason 
The frequency of cold sensitivity impairment was 
higher in type 2 diabetics than in type 1 (60% vs. 40%) 
The impairment of heat sensitivity was only found in 
10% of type 1 diabetics. 
The frequency of vibration sensitivity impairment was 
higher in type 2 diabetics than in type 1 (45% vs. 15%) 
The impairment of pain sensitivity was not found in 
neither group of diabetics. 
Mean duration 
of DM 
T1 7.8 ± 2.3 





T1 9.4 ± 0.6 
T2 8.3 ± 0.3 
Gender (%) ♀ 54.8% 
♂ 45.2% 
Age (mean) 46.3 ± 2 
48%
Age (mean) 50 ± 15
Kramer et al.
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N 112 Exercise electrocardiography (at different
intervals): heart rate and blood pressure at
rest and estimated workload in metabolic
equivalents (METs).
CV autonomic reflex tests: heart rate response
to Valsalva maneuver, beat-to-beat heart rate
variation. Heart rate response to standing.
Postural fall in blood pressure. Assessment of
diastolic blood pressure response during
sustained handgrip.
Autonomous cardiac neuropathy, d tected by tests of variability of HR with exercise, was related to
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3.2. Motor Neuropathy
The main characteristics of studies comparing somatic motor neuropathy at the level
of skeletal muscles in type 1 and 2 diabetic patients are shown in Table 2. Balducci et al. [15]
evaluated muscle strength by isometric contractions by measuring the maximal voluntary
contractions performed at the shoulder press along the sagittal plan, and between the
upper arm and the trunk, respectively, for the upper body, and at the leg extension machine
at the knee and the hip, for the lower body. No significant association with any type
of diabetes was found in the multivariate model when taking into account confounders
influencing muscle strength such as age, sex, and physical activity level. Among neuro-
electrophysiological alterations, only motor and sensory nerve amplitudes measured in
the peroneal motor nerve and sural sensory nerve, respectively, correlate with muscle
strength when corrected for the confounding factors mentioned above. In contrast, the
conduction velocities and distal latencies are not associated with muscle strength, and
all these data suggest that in the early stages, diabetic polyneuropathy mainly consists
of axonal damage, whereas later myelin involvement accounts for reduced conduction
velocity and latency, which is observed only in specific cases or at later stages. The motor
nerve conduction velocity measured in the median and peroneal motor nerves (with the
ulnar motor nerve tending towards significant) was significantly lower in type 2 than in
type 1 diabetic patients [21].
However, Balducci and co-workers [15] did not detect any difference between type 1
and 2 diabetic patients for velocity and latency measured in the peroneal motor nerves,
whereas a tendency (p = 0.08) was observed for the amplitude of peroneal motor nerve.
The difference in the mean age of participants belonging to the type 1 diabetes group may
have played a role in this difference in motor nerve velocity in these two studies (the mean
age in Balducci’s study was 46 years, and in Scamarek’s study [21] it was 61 years for the
group of patients with type 1 diabetes, whereas the mean age in both studies for diabetic
type 2 patients was 66 years). In the upper body motor nerves, Arnold et al. [24] evaluated
the compound muscle action potentials from the abductor pollicis brevis muscle using
surface electrodes following stimulation of the median nerve at the wrist. All patients
(type 1 and 2 diabetes patients, age-, sex-, HbA1c level- and disease-duration-matched)
had normal sural nerve conduction amplitudes, and none of them reported neuropathic
symptoms or demonstrated any clinical evidence of neuropathy as quantified by pin prick
and vibration sensitivity or ankle-deep tendon reflexes. Only the type 1 patients showed
abnormalities in nerve excitability recordings, consisting of reductions in the prolongation
of the relative refractory period and reductions in superexcitability, and this pattern was
probably due to a pattern of axonal depolarization as a result of either a dysfunction of the
energy-dependent axonal Na+/K+ pump in isolation or due to microvascular perfusion
deficits leading to ischemia. This study provides evidence that altered axonal function
precedes the onset of clinical neuropathy in type 1 diabetes.
3.3. Autonomic Neuropathy
The main characteristics of studies comparing type 1 and 2 diabetic patients regarding
neuropathy at the level of the autonomic (sympathetic and parasympathetic) nervous
system in the skeletal muscles are shown in Table 3. Heart rate variability was the most
extensively investigated parameter in those studies, comparing type 1 and type 2 car-
diac dysautonomy [29,36,37]. Autonomic cardiac neuropathy is diagnosed when there
are two or more abnormal results of autonomic function tests [38] and its prevalence is
high in diabetic patients, ranging between 20 and 60% [28,29,31,39]. The prevalence of
cardiac autonomous neuropathy has been reported either to be higher in type 2 diabetic
patients [29,40,41] or similar in both types of diabetes in other reports [31,32,35,42]. Re-
garding the component of autonomic nervous system, it seems to be affected more by the
parasympathetic rather than the sympathetic one [31,39,41].
However, a careful analysis of the tools used to measure cardiac autonomous neu-
ropathy revealed the differences according to the test used to assess it. Heart rate response
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related to parasympathetic system activation following deep breathing and standing are
higher (more impaired) in type 1 than in type 2 patients [15,17], as well as the heart rate
variation at rest [17,19]. In contrast, heart rate variability in response to the Valsalva ma-
neuver and the dispersion of QTc interval (QT interval corrected for heart rate) in the
electrocardiogram was more impaired in type 2 diabetic patients [17,33]. A combination of
the Valsalva and lying-to-standing tests provided the highest sensitivity for detecting car-
diac autonomous neuropathy in type 1 diabetic patients (sensitivity = 97.6%, AUC = 0.887)
while for type 2 diabetes patients, the deep-breathing and Valsalva test had the highest
values (sensitivity = 83.6%, AUC = 0.856) [28]. There were associations between cardiac
autonomic neuropathy and long-term complications of diabetes [31,32,35]. Alterations
of heart variability during exercise were observed in type 1 and 2 patients with diabetic
retinopathy, e.g., less increase in heart rate during exercise and lower recovery rates in
patients with diabetic retinopathy, although the pattern of those changes was more im-
paired in type 1 diabetic patients [35]. There were significant associations between cardiac
autonomic neuropathy and hypertension, and between the cardiac autonomic neuropa-
thy/hypertension profile and micro- and macro-angiopathic complications of diabetes [31]
and the prolongation of the QTc interval in electrocardiograms [32,33]. Erectile dysfunction
(ED) is a common complication of diabetes, and an important cause of decreased quality of
life in diabetic men, and its prevalence ranges from 20 to 70% [26,27,43–45]. The presence
of autonomic neuropathy is one of the pathophysiological hallmarks for erectile dysfunc-
tion in diabetes [46,47]. Erectile dysfunction affects both types of diabetes, but it is more
prevalent in type 2 patients after controlling for age, but the opposite may be true when
other concomitant long-term diabetic complications are present [26,27], and in patients
(type 1 and 2) with other diabetic complications (neuropathy, vascular diseases, retinopa-
thy, and nephropathy as well as hypercholesterolemia and hypertension) [26,45]. The
existence of a diabetic neuropathy affecting stomach and gallbladder function in diabetic
patients has been investigated by means of ultrasound techniques [33,34]. Gastroparesis is
a frequent complication of diabetes, and autonomic neuropathy seems to be a cornerstone
pathophysiological feature [48]. Gastric emptying is more impaired in type 2 than in type 1
diabetic patients, and in both types, it correlates with cardiac autonomic neuropathy (by
means of electrocardiogram QTc segment dispersions) and long-term complications such as
diabetic retinopathy and nephropathy [33]. In all diabetic individuals, gallbladder volume
progressively decreased after ingestion of the test meal, while the residual volumes were
larger in diabetics than in healthy controls. However, there were no significant differences
in gallbladder motor function parameters between type 1 and type 2 patients, but com-
pared to healthy subjects, subjects with autonomic neuropathy did exhibit a larger residual
gallbladder volume and less complete emptying with earlier gallbladder refilling [34,49].
3.4. Differences in Molecular Markers Associated with Neuropathy in Type 1 and 2 Diabetes
The pathophysiology mechanisms underlying neuropathy can develop differently in
the two types of diabetes, with different associations between the biomarkers. Regarding
subclinical inflammation markers, patients with type 2 diabetes showed higher blood levels
of inflammatory markers such as high-sensitivity C-reactive protein, pro-inflammatory
cytokines IL-6, IL-18, soluble cell adhesion molecules and E-selectin and ICAM-1, than
in type 1 diabetes patients [19,21]. By contrast, the blood levels of adiponectin, an adipocyte-
derived protein with multiple paracrine and endocrine activities (anti-inflammatory, insulin-
sensitizing and proangiogenic effects) are higher in type 1 than in type 2 diabetic pa-
tients [21]. The associations between biomarkers and neuropathy and the differences
between type 1 and type 2 diabetics have been scarcely studied [19,21]. In type 1 diabetes,
there is an association between adiponectin levels and motor (but not sensory) nerve con-
duction velocity, whereas in type 2 patients, the adiponectin levels correlate with both motor
and sensory nerve velocities after controlling for several confounders (age, sex, time since
diagnosis of diabetes, HbA1c, waist circumference, height, total cholesterol, hypertension,
current smoking, physical activity, use of lipid-lowering medication, use of nonsteroidal
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anti-inflammatory drugs, history of myocardial infarction and/or stroke). In type 2 diabetic
patients, elevated IL-6 levels in blood associate with the impairment of motor nerve func-
tion (but not at the sensory nerve level) and the development of sensorimotor neuropathy
in diabetic patients measured at the level of median, ulnar and peroneal motor nerves
and the median, ulnar and sural sensory nerves [21]. Adiponectin levels were associated
with nerve conduction velocity and diabetic neuropathy in type 1 and 2 diabetes, although
in opposite directions, e.g., higher levels of high-molecular weight adiponectin. Total
adiponectin and their ratio were associated with prevalent neuropathy and both reduced
motor and sensory nerve conduction velocity, whereas no consistent associations were
observed for other inflammatory markers such as the concentration in blood of C-reactive
protein, IL18, soluble intercellular adhesion molecule-1 and E-selectin. In type 1 diabetes,
only high-molecular weight adiponectin and total adiponectin concentrations showed
positive associations with motor nerve conduction velocity. Osteoprotegerin (OPG), also
known as “osteoclastogenesis inhibition factor”, is a soluble receptor that belongs to the
tumor necrosis factor receptor superfamily [50,51]. OPG has a decoy function towards
two ligands of tumor necrosis factor receptors: RANKL and TRAIL. Osteoprotegerin acts
by binding to RANKL, thereby preventing the interaction of the RANK receptor with its
ligand, and inhibiting osteoclast differentiation and survival. It also has an antagonistic role
for the apoptosis-inducing ligand receptor TRAIL [23,51]. OPG therefore has an inhibitory
effect on osteolysis, and acts as an inhibitor of vascular calcification, which is closely related
to osteoporosis and arteriosclerosis. In diabetes, distal symmetric neuropathy is associated
with arterial calcification and osteopenia, and these processes are believed to occur due to
abnormal functioning of the OPG/RANKL system [52,53]. Plasma osteoprotegerin levels
are related to peripheral neuropathy in both types of diabetes, although the strongest
relationship is in type 2, and linked to other long-term complications such as peripheral
arterial disease and nephropathy [23]. The innate immune response receptor Toll-like
receptor 4 (TLR4) belongs to the pattern recognition receptor family, whose activation leads
to an intracellular signaling pathway NF-κB and inflammatory cytokine production [54].
There is a strong association of the genetic polymorphisms Asp299Gly/Thr399Ile of TLR4
with reduced prevalence of peripheral neuropathy in type 2 diabetic patients (but not in
type 1 diabetic patients) [55] raising the question of whether the innate immune response
may be involved in the pathogenesis of neuropathy in type 2 diabetes [56].
3.5. Effect of Age and Sex on Neuropathy in Type 1 and 2 Diabetes Patients
The study of the influence of age and gender as independent risk factors in the de-
velopment of neuropathy in type 1 and type 2 diabetic patients has rarely been addressed
by the scientific community. Only six articles [21,23,24,28,32,55] have assessed the contri-
bution of age and gender variables in the development of sensory, motor or autonomous
neuropathy by type of diabetes. An advanced age better fits in statistical models for neu-
ropathy severity in type 2 diabetic patients [21,23,24,28,32]. In research conducted by Pan
et al. 2019 [28], neither age nor gender were independent factors for the development of
cardiac autonomic neuropathy in type 1 diabetic patients. However, an older age was a
significant risk factor in the type 2 group. Schamarek et al. 2016 [21], in their study on the
association between inflammation biomarkers and sensorimotor neuropathy in diabetics,
analyzed the influence of age and gender factors on different variable associations. Among
type 1 diabetics, no biomarker was related to the presence of a diabetic sensorimotor
neuropathy, but motor nerve conduction velocity (NCV) was inversely associated with
C-reactive protein, IL6 and soluble ICAM-1 in an age- and gender-adjusted model, and
adiponectin levels were associated with sensory NCV, although the statistical significance
of those associations were lost after adjustment for other factors. Among type 2 diabetics,
sensorimotor neuropathy was associated with IL6 and adiponectin levels in an age and
gender analysis. In a correlation analysis, Arnold et al. 2012 [24] observed that there was
no association between different nerve excitability parameters such as determinants of
axonal function, and the “age” factor in type 1 diabetics, whereas they found a significant
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association with type 2 diabetics. The presence of peripheral neuropathy was associated
with plasma concentrations of osteoprotegerin in an age- and gender-adjusted model in
both type 1 and type 2 diabetics [23]. Pappachan et al. [32] showed that advanced age
was a risk factor for the development of cardiac autonomic neuropathy in both types of
diabetes, while gender did not suppose an additional risk in any of the groups. Finally, age
and gender did not influence the association of diabetic neuropathy and the Asp299Gly
and Thr399Ile genotypes in type 2 diabetics, while there was no association in type 1
subjects [55].
4. Discussion
Evidence indicates that there are important pathophysiological differences between
type 1 and type 2 diabetes, and consequently, it is logical that there may be also differences
between the complications derived from each type [4,57]. Due to the differences in the
underlying pathology and in the related factors, diabetic polyneuropathy occurs differently
in each type of diabetes, causing different functional deficits [57–61]. Studying and knowing
these peculiarities is essential for effective prevention, diagnosis, and treatment.
The present study shows that there are differences between type 1 and type 2 diabetes
regarding the symptoms of sensory neuropathy. In general, most of the results show a
greater impairment of both superficial sensitivity (thermoalgesia) and deep sensitivity
(vibration) in type 2 diabetics than in type 1 diabetics. Partanen et al. [62], indicated that
the symptoms of sensorimotor neuropathy manifest earlier during the course of type 2
diabetes than they do in type 1 diabetes. Considering this, and looking at the results of
this review, it is possible that sensory nervous impairment occurs earlier in type 2 diabetes
than in type 1, or that perhaps it may be more acute. However, despite observing a greater
impairment of thermal sensitivity in type 2 diabetics, when specifically analyzed, the heat
sensitivity was only found impaired in type 1 diabetes [17]. This phenomenon may be
explained by the fact that although thermal sensitivity travels through small nerve endings,
the fibers responding to heat and cold stimuli are different in terms of their typology and
characteristics. Heat sensitivity is transmitted through C-type unmyelinated fibers, while
cold is transmitted through Aδ-type myelinated fibers [63,64]. For this reason, each type of
thermal nerve fiber may deteriorate differently during the course of the disease. Several
papers analyzed in the present study [15,17,19,33] show that the nervous impairment of
palestesic sensitivity is greater among type 2 diabetics, or that it predominates in this group,
as mentioned above. The reduced sural sensory nerve amplitude in both groups of diabetes
is compatible with axonal degeneration, which is more prevalent in the early stages of
diabetic peripheral neuropathy [65,66]. Moreover, the nerve conduction rate, which is
lower in type 2 diabetics, reflects the impairment of myelin at a later stage [15,21].
Considering the physiology of the somatosensory pathways [63], it is curious that
both superficial sensitivity (primarily thermal sensitivity to cold) and deep sensitivity (such
as palestesic sensitivity), deteriorate mainly in type 2 diabetes, since they travel through
different sensory pathways. However, if we look at the nervous anatomy of these pathways,
we can see that the short fibers that transmit cold are myelinated, while those that transmit
vibration are large fibers that are also myelinated [67]. The fact that the sensitivity that
travels through myelin fibers is more affected in type 2 diabetics is an interesting issue that
should be resolved in future research.
Muscle weakness is one of the later complications of diabetic neuropathy, and accord-
ing to the evidence, there is a relationship between reduced muscle strength and peripheral
motor nerve dysfunction [68–70]. In our review, only one study has compared motor nerve
impairment between type 1 and type 2 diabetes patients. It examined the association
between the deterioration of muscle strength and the type of diabetes, and concluded that
there were no differences between the two types of diabetes [15]. The lack of studies with
which to compare this result prevents a complete analysis for establishing a conclusion
in this regard. It has been suggested that continuous exposure to high concentrations of
glucose causes early metabolic alterations in the nerves and a decline in Na+/K+-ATPase
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activity, as well as an impairment of microvascular perfusion [71–73]. Likewise, it appears
that the axonal function was altered in patients with type 1 diabetes, but the patients did
not present symptoms of motor neuropathy [24]. It is possible that an early approach may
prevent the development of motor neuropathy with irreversible damage [24,62].
Cardiac autonomic neuropathy (CAN) is one of the diabetic complications with the
greatest impact at a clinical level, but is nevertheless one of the most underdiagnosed [61,74].
According to the published studies, the prevalence of CAN appears to be variable in both
types of diabetes. While it ranges between 2 and 91% in type 1 diabetes, it ranges between
25 and 75% in type 2 diabetes [40,75]. The fact that several different tests are used to
diagnose this condition and the lack of consensus in its diagnosis may be the cause of
undiagnosed cases and consequently, considerable variability in its prevalence [74]. Ac-
cording to the study by Pan et al. 2019 [28], the most sensory way to diagnose CAN is by a
combination of certain tests; for type 1 diabetics it is the Valsalva maneuver together with
the lying-to-standing test, for type 2 diabetics it is the combination of deep-breathing and
the Valsalva test. In our findings, we observed that there is a greater sympathetic than
parasympathetic impairment, as indicated by the screening tests for autonomic cardiac
neuropathy [15,17,19,28,29,31–33,35]. These results are consistent with the research of
Pourmoghaddas and Hekmatnia [76] who confirmed that parasympathetic abnormality
was three times greater than the sympathetic affectation in diabetic CAN. Furthermore,
tests that examine parasympathetic activity, such as HR response 15 and 30 s after changing
position, HR response during deep respiration and HR response during Valsalva maneuver,
were found to be more impaired in type 2 diabetics [15,17,19,33], with the exception of the
HR variation test during rest, which was more affected in type 1 diabetics [17,19]. These
results seem to indicate that the most altered autonomic nervous component in CAN is
the parasympathetic system, and that it is altered above all in type 2 diabetics. The asso-
ciation between autonomic cardiac neuropathy and retinopathy in diabetic subjects [35]
has been verified in other studies in type 1 diabetics [77] and in type 2 diabetics [78]. The
correlation between CAN and hypertension has been well documented. These findings
suggest that the possible cause of this association is sympathetic hyperactivity and a loss of
parasympathetic regulation, which lead to an increase in the heart rate [79,80]. The high
prevalence of CAN in type 2 diabetes, can synergize with the adverse effects on cardiovas-
cular system induced by other common comorbidities such as hypertension, dyslipidemia
and obesity [81–83] which contribute to premature morbidity and mortality [84–86]. In our
review, the prevalence of erectile dysfunction was higher in type 2 diabetics. As for other
disorders derived from autonomic neuropathy, erectile dysfunction is a typical complica-
tion of diabetes [87–90], but only two studies compared it in both types of diabetes [26,27].
Further studies are also needed to compare disorders such as gastroparesis and gallbladder
function of neuropathic origin in the two types of diabetes [33,34].
One of the modifiable factors that may be related to the development of diabetic
neuropathy, especially in people with diabetes, is obesity, which is an entity that is often
comorbid, especially in type 2 diabetic patients [19,31]. It is well-know that autonomic
nervous system dysfunction has a bidirectional relationship with obesity [91]. On the one
hand, there is good scientific evidence that alterations of the autonomic nervous system
could be involved in the pathogenesis of obesity, and on the other hand, obesity (especially
central, visceral obesity) induces autonomic nervous system dysfunction, which may be
involved in hemodynamic and metabolic alterations that increase the cardiovascular risk of
obese individuals such as the insulin resistance, among others, which increases the risk of
type 2 diabetes [91,92]. According to this, the autonomic neuropathy in diabetics was more
prevalent in obese patients. Regarding the incidence of cardiac autonomic neuropathy,
it was higher in obese patients with type 2 diabetes which also adds higher odds to
present comorbid arterial hypertension [29,31]. The incidence of erectile dysfunction and
alterations in fasting gallbladder volume and less complete emptying increased with
increasing body-mass index [27,34]. In contrast to autonomic neuropathy, BMI seems to
not play a significant role on motor nerves alterations in diabetic patients [24], however
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much work should be done regarding sensorimotor neuropathy and obesity, taking into
account that weight reduction significantly improved autonomous dysfunction in obesity
and likely autonomic neuropathy in diabetes [91].
Regarding peripheral biomarkers associated to neuropathy, some of those are related
to chronic inflammatory state such as the inflammatory cytokine IL-6 [93], and to the innate
immune response receptor TLR4 [55] associated more frequently to the severity of neuropa-
thy in type 2 diabetes patients. In type 1 diabetes, the most promising biomarker related to
neuropathy appearance and severity is adiponectin, the richest adipokine in human plasma
mainly secreted from white adipose tissue. Changes in the concentration of adiponectin
isoforms in blood have also demonstrated in type 2 diabetes [94]. These differences in
peripheral biomarkers might contribute to the pathophysiological progression of various
diabetic neuropathy types and symptoms and it clearly deserves further studies.
The increase in life expectancy worldwide in recent decades, particularly among
women, has meant that people with diabetes live longer with the disease and therefore
suffer from its complications, with the most prevalent being diabetic neuropathy [95,96]. As
a result, it is important to study age and gender as risk factors involved in the development
of diabetic neuropathy. However, only six articles in this study have examined these issues.
In their study, Grisold et al. [97] recently pinpointed that age and gender are possible
risk factors for the development of diabetic peripheral neuropathy in type 1 and type 2
diabetes, although their exact contribution is unknown. After reviewing the articles, age
was observed to be a risk factor in the development of autonomic cardiac neuropathy and
motor neuropathy, with the latter measured in parameters of motor nervous excitability,
and in both cases this relationship was only found in type 2 diabetics [24,28]. However, a
relationship was detected between CAN and the “advanced age” factor in both type 1 and
type 2 diabetic patients [32]. These results suggest that older age, which is a more typical
characteristic in studies of type 2 diabetics, is a risk factor for diabetic neuropathy. With
regard to the influence that gender could have in this aspect, little research has been done
and no relationship has been found.
Diabetic neuropathy is the most common complication of diabetes mellitus and the
one that has the greatest impact on the life of the patient, with high rates of morbidity and
mortality. Knowing how sensory, motor, and autonomic neuropathy affects each type of dia-
betes and their differences and similarities is essential for developing an adapted diagnostic
and therapeutic plan in order to better address the disease and avoid irreversible damage.
This review has identified several aspects that require future research. One of the
unknown factors identified is the different involvement of the nerve fibers responsible for
each sensory function, and its possible relationship with its characteristic anatomy and
physiology function or dysfunction in diabetes. Motor neuropathy and its peculiarities,
typical of type 1 and type 2 diabetes, require a great deal of attention since it is the least
investigated neuropathy domain investigated so far. As for autonomic neuropathy, it is
important to clarify the mechanism of sympathetic and parasympathetic involvement in
both types of diabetes, as well as the related disorders to alterations or autonomic nervous
system. In this way, the characterization of the disease subtype will improve the diagnosis
and treatment of neuropathy and it will consequently allow a more personalized and
effective treatment besides glycemic index control.
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